Report overview
Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
This report contains market size and forecasts of Oral Mucositis Drugs for Cancer Therapy in global, including the following market information:
Global Oral Mucositis Drugs for Cancer Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oral Mucositis Drugs for Cancer Therapy Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oral Mucositis Drugs for Cancer Therapy companies in 2021 (%)
The global Oral Mucositis Drugs for Cancer Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Mouthwash Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oral Mucositis Drugs for Cancer Therapy include 3M Healthcare, GSK, Pfizer, Colgate-Palmolive, Norgine, Sobi, Bausch Health, EUSA Pharma and Camurus, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Mucositis Drugs for Cancer Therapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Mucositis Drugs for Cancer Therapy Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Mucositis Drugs for Cancer Therapy Market Segment Percentages, by Type, 2021 (%)
Mouthwash
Pain Control Medication
Other
Global Oral Mucositis Drugs for Cancer Therapy Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Mucositis Drugs for Cancer Therapy Market Segment Percentages, by Application, 2021 (%)
Chemotherapy
Radiotherapy
Global Oral Mucositis Drugs for Cancer Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Mucositis Drugs for Cancer Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Mucositis Drugs for Cancer Therapy revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oral Mucositis Drugs for Cancer Therapy revenues share in global market, 2021 (%)
Key companies Oral Mucositis Drugs for Cancer Therapy sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oral Mucositis Drugs for Cancer Therapy sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Sobi
Bausch Health
EUSA Pharma
Camurus
Clinigen Group
Helsinn Healthcare
Alliance Pharma
